OZEM
Roundhill Glp-1 & Weight Loss ETF
Price Chart
Latest Quote
$31.02
+0.71 (+2.33%)
Current Price
| Previous Close | $30.31 |
| Open | $30.50 |
| Day High | $31.08 |
| Day Low | $30.50 |
| Volume | 23,275 |
Fund Information
| Quarterly Dividend / Yield | N/A / 1.29% |
| Net Assets | $50.15M |
| Expense Ratio | 0.59% |
| Category | Health |
| Fund Family | Roundhill Investments |
| Net Asset Value | $30.37 |
| Premium/Discount | 2.12% |
| Quarterly Dividend Yield | 1.29% |
| P/E Ratio | 13.85 |
| Exchange | NGM |
📊 ETF Analysis
Company Data
Financial Ratios
Returns & Margins
Ownership
| Insider & Institutional transactions data not available |
Valuation Ratios
Analyst Data
Technical Indicators
| SMA20 | $30.71 |
| SMA50 | $31.09 |
| SMA200 | $31.43 |
| RSI | 49.06 |
| ATR | 0.6511 |
| Rel Volume | 1.03 |
Performance History
| Week | +1.49% |
| Month | +1.61% |
| Quarter | +3.16% |
| 6 Months | -6.44% |
| YTD | -9.68% |
| Year | +20.65% |
| 10 Years | +23.96% |
ETF Scoring Not Available
Exchange-traded funds (ETFs) are not scored using our fundamental analysis metrics, as they represent baskets of securities rather than individual companies.
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-22 | $31.01 | 23,400 |
| 2026-06-18 | $30.39 | 12,700 |
| 2026-06-17 | $30.51 | 9,600 |
| 2026-06-16 | $30.48 | 13,000 |
| 2026-06-15 | $30.78 | 22,700 |
| 2026-06-12 | $30.56 | 6,800 |
| 2026-06-11 | $30.85 | 13,800 |
| 2026-06-10 | $29.89 | 28,900 |
| 2026-06-09 | $30.08 | 83,500 |
| 2026-06-08 | $29.79 | 27,700 |
| 2026-06-05 | $30.46 | 15,400 |
| 2026-06-04 | $30.91 | 23,100 |
| 2026-06-03 | $30.08 | 17,300 |
| 2026-06-02 | $30.30 | 39,000 |
| 2026-06-01 | $31.13 | 17,500 |
| 2026-05-29 | $31.76 | 14,700 |
| 2026-05-28 | $31.55 | 18,300 |
| 2026-05-27 | $31.41 | 17,700 |
| 2026-05-26 | $31.08 | 18,700 |
About Roundhill Glp-1 & Weight Loss ETF
The fund's manager will invest at least 80% of its net assets (plus any borrowings for investment purposes) in the equity securities of GLP-1 & Weight Loss Companies or any derivative instruments (such as swap agreements or forward contracts) that utilize one or more GLP-1 & Weight Loss Companies as the reference asset. The fund is non-diversified.
📰 Latest News
3 Non-Pharma Firms That Could Benefit From the GLP-1 Trend
MarketBeat • 2026-06-20T12:45:00Z
Inside the GLP-1 Boom: ETF Picks for the Obesity Drug Market
Zacks • 2026-06-10T16:00:00Z
GLP-1 Drug Giants Race to Go Global With Their Obesity Pills: ETFs to Gain
Zacks • 2026-05-19T18:27:00Z
Scoring 2 Million Prescriptions, Novo’s GLP-1 Pill Crushes Expectations
The Daily Upside • 2026-05-07T04:01:00Z
3 Ways to Invest in the Growing GLP-1 Weight Loss Market
MarketBeat • 2026-04-17T15:20:00Z
FDA Clears NVO's Higher Dose of Wegovy: Diversify With These Health ETFs
Zacks • 2026-03-23T15:27:00Z
Healthcare ETFs to Watch as Novo Nordisk Tumbles on Poor Sales Outlook
Zacks • 2026-02-04T14:30:00Z
Ozempic, Mounjaro, Wegovy, or Zepbound? This ETF Holds Them All
MarketBeat • 2026-01-19T20:23:00Z
2 under-the-radar ETFs retail investors should jump on
Yahoo Finance Video • 2026-01-07T11:00:38ZThe Obesity Pill Rush: Healthcare ETFs to Gain as FDA Nods to Novo Drug
Zacks • 2025-12-29T13:46:00Z
Period:
Loading...
No financial data available yet. Financial data will be fetched automatically.